Low-molecular-weight Heparin (enoxaparin) versus unfractionated heparin for venous thromboembolism prophylaxis in patients undergoing craniotomy

Clin Neurol Neurosurg. 2022 Dec:223:107482. doi: 10.1016/j.clineuro.2022.107482. Epub 2022 Oct 20.

Abstract

Objective: To explore the difference in post-operative DVT, PE, and ICH complications following administration of prophylactic UFH or enoxaparin in patients undergoing craniotomy.

Methods: A retrospective chart review was conducted for 542 patients at our institution receiving either 5000units/0.5 mL UFH (BID or TID; 180 patients) or single daily 40 mg/0.4 mL enoxaparin (362 patients) following craniotomy. Multivariate linear regression models were developed comparing rates of postoperative DVT, PE, and reoperation for bleeding in patients given enoxaparin versus UFH prophylaxis while controlling for age at surgery, history of VTE, surgery duration, number of post-operative hospital days, reoperation, post-operative infections, and reason for surgery (tumor type, genetics, etc.). Mann Whitney U tests were subsequently performed comparing rates of postoperative DVT, PE, and ICH for each group.

Results: Patients receiving prophylactic enoxaparin, when compared to UFH, exhibited similar rates of postoperative DVT (22 % vs 20.6 %, p = 0.86), PE (9.7 % vs 8.9 %, p = 0.86), and reoperation for bleeding (0.4 % vs 0.2 %, p = 0.58), while controlling for the factors described above.

Conclusion: In patients undergoing craniotomy, rates for DVT, PE, and ICH were similar between patients treated with either prophylactic enoxaparin or UFH. Further studies are needed to understand whether a certain subset of patients demonstrate improved benefit from either prophylactic anticoagulant.

Keywords: Craniotomy; Embolism; Enoxaparin; Heparin; Thrombosis.

MeSH terms

  • Anticoagulants / adverse effects
  • Craniotomy / adverse effects
  • Enoxaparin* / adverse effects
  • Hemorrhage / drug therapy
  • Heparin / adverse effects
  • Heparin, Low-Molecular-Weight / adverse effects
  • Humans
  • Retrospective Studies
  • Venous Thromboembolism* / drug therapy
  • Venous Thromboembolism* / prevention & control

Substances

  • Enoxaparin
  • Heparin
  • Heparin, Low-Molecular-Weight
  • Anticoagulants